CXCR4 and colorectal carcinoma: We have then tracked the biodistribution of the original unlabeled T22-GFP-H6 nanoparticle (measuring its intrinsic green fluorescence) and the resulting two labeled variants (T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5) upon intravenous administration in animal models bearing human, CXCR4+ diffuse large B-cell lymphoma (DLBCL) or colorectal cancer (CRC).